View allAll Photos Tagged Stemcell
Nevada Lt. Governor Brian Krolicki, center, stands with Cord Blood America co-founders Stephanie Schissler, from left, and Matthew Schissler, former Lt. Governor Lonnie Hammargren and Nevada Development Authority President Somer Hollingsworth near the stage during the grand opening of the Cord Blood America corporate office and lab in Las Vegas Friday, January 22, 2010. Cord Blood America is an umbilical cord blood stem cell preservation company. (Source: LEILA NAVIDI / LAS VEGAS SUN)
Amanda Cool of Smart Cells International explains how stem cell treatments can be of benefit to different ethnic groups. www.smartcells.com
Wendy L. Currie, Editor-In-Chief, Health Policy and Technology
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Supervit c + stemcell
ąøŖąøøąøąø¢ąøąøąøąø±ąø§ąøą¹ąø§ąø¢ą¹ąø«ą¹ąøąø“ąø§ąøąø²ąø§ą¹ąø„ąø° ą¹ąøąø«ąøą¹ąø²ąøąø£ąø°ąøą¹ąø²ąøą¹ąøŖąøąø¶ą¹ąøąøą¹ąø§ąø¢ąøąø„ąø±ąø ąøŖąø²ąø£ąøą¹ąø²ąøąøąøąøøąø”ąø¹ąø„ąøąø“ąøŖąø£ąø°ąøŖą¹ąøąøą¹ąø²ąøąøą¹ąøąøąøąø“ą¹ąøąøą¹ąøą¹ąø²ąøŖąø¹ą¹ąøąø“ąø§
ąøąø£ąø°ąøąøøą¹ąøąøąø²ąø£ą¹ąø«ąø„ą¹ąø§ąøµąø¢ąøą¹ąøą¹ąøąø“ąø§ ąøąøąø±ąøą¹ąøąø„ąøąø“ąø§ąøąøµą¹ąøąø²ąø¢ą¹ąø„ą¹ąø§ ąøąø£ąø°ąøąøøą¹ąøąøąø²ąø£ąøŖąø£ą¹ąø²ąøą¹ąøąø„ąø„ą¹ąøąø“ąø§ą¹ąø«ąø”ą¹ąøą¹ąø§ąø¢ą¹ąø«ą¹ą¹ąøąø«ąøą¹ąø²ą¹ąøŖąøąø¢ą¹ąø²ąøąøą¹ąøąøą¹ąø¢ąø
ąøą¹ąø§ąø¢ąøąø²ąø£ąøąøŖąø”ąøąøŖąø²ąøąøąø²ąø£ąøąø³ąøąø²ąøąø§ąø“ąøąø²ąø”ąø“ąøąøąøµ ą¹ąø„ąø°ąøŖą¹ąøąø”ą¹ąøąø„ąø„ą¹ąøąø±ą¹ąøąø¢ąøąøąøąø²ąø ąøŖąø§ąø“ąøŖą¹ąøąøąø£ą¹ą¹ąø„ąøąøą¹
ą¹ąøąø¢ą¹ąø«ą¹ąøąø“ąø§ąøąø²ąø§ą¹ąøąøµąø¢ąøą¹ąøą¹ąø²ąøąø±ąøąøąø²ąø£ąø„ąøąøąø«ąøą¹ąø² ąøąø£ąøąøąø“ąø§ ą¹ąøąøąøąøą¹ąø ąø«ąø£ąø·ąøą¹ąøą¹ąø
ą¹ąø„ą¹ąø§ąø¢ąø±ąøąøą¹ąø§ąø¢ąøąø²ąø£ąøąø³ąøąø§ąø²ąø”ąøŖąø°ąøąø²ąøąøąø“ąø§ąøąø²ąøąøŖąø“ą¹ąøąøąøµą¹ąøąøąøą¹ąø²ąøąøąø±ą¹ąøą¹ąøą¹ąøąø±ą¹ąøąøąøą¹ąøąøąøąøąø¶ąøąøąø“ąø§ąø«ąøąø±ąøąøąø±ą¹ąøąø«ąø”ąøą¹ąø ąøąø£ąø“ą¹ąø§ąøąøąø±ą¹ąø
ąøąø£ą¹ąøąø”ąøąø±ąøąøąø±ą¹ąøąøą¹ąøąø°ąø”ąøµąøąø²ąø£ąøąø£ąø°ąøąøøą¹ąøąø£ąø°ąøąøąø«ąø”ąøøąøą¹ąø§ąøµąø¢ąøą¹ąøąøąø“ąø§ąø«ąøąø±ąøąøąø³ą¹ąø«ą¹ą¹ąøąø“ąøąøąø²ąø£ąøąø³ąøąø±ąøąøąøąøą¹ąøŖąøµąø¢ą¹ąøąøąø“ąø§ąøąø±ą¹ąøąø„ąø¶ąø
ą¹ąø„ąø°ąø”ąøµąøąø²ąø£ąøŖąø£ą¹ąø²ąøą¹ąøŖą¹ąøą¹ąø¢ąøąøąø„ąø„ąø²ą¹ąøąøą¹ąø„ąø°ąøąø§ąø²ąø”ąø¢ąø·ąøąø«ąø¢ąøøą¹ąøą¹ąø«ą¹ąøąø“ąø§ąøąøµąøąøą¹ąø§ąø¢
ąøąø£ą¹ąøąø”ąøąø£ąø°ąøąøøą¹ąøąøąø²ąø£ąøąø„ąø±ąøą¹ąøąø„ąøąø“ąø§ąø«ąøąø±ąøąøąø±ą¹ąøąøąøąøąøąø³ą¹ąø«ą¹ą¹ąøą¹ąøąø“ąø§ą¹ąø«ąø”ą¹ąøąøµą¹ąøąø¹ąøŖąøą¹ąøŖą¹ąø„ąø°ąø”ąøµąøŖąøøąøąø ąø²ąøąøąøµ
ą¹ąø„ą¹ąø§ąø¢ąø±ąøą¹ąø«ą¹ąøąø“ąø§ąø«ąø„ąø±ą¹ąøąøŖąø²ąø£ąøą¹ąø³ą¹ąø„ąø°ąøąøąøąøąø“ą¹ąøąøą¹ąø«ą¹ąøąø±ąøąøąø“ąø§ąø«ąøąø±ąø ąøąøµą¹ąøąø³ą¹ąø«ą¹ąøąø“ąø§ąøąø²ąø§ąøąø£ąø°ąøą¹ąø²ąøą¹ąøŖą¹ąøąøąøąø£ąøąøŖąø¹ąøąø£
ąøąø¶ą¹ąøąø«ąø„ąø±ąøąøąø²ąø£ąøąø³ąøąø²ąøą¹ąøąøąøąøµą¹ąøŖąø²ąø”ąø²ąø£ąøąøą¹ąø§ąø¢ą¹ąøąøąø²ąø£ąøąø„ąø±ąøą¹ąøąø„ąø„ą¹ąøąø“ąø§ąøąø³ąøąø§ąø²ąø”ąøŖąø°ąøąø²ąøąøąø“ąø§ą¹ąøą¹ąøąø¢ą¹ąø²ąøąø„ą¹ąø³ąø„ąø¶ąø
ą¹ąøąø“ą¹ąø”ąøąø§ąø²ąø”ąøąøøą¹ąø”ąøąø·ą¹ąøąøąø£ą¹ąøąø”ąøąø±ąøą¹ąø«ą¹ąøŖąø²ąø£ąøąø²ąø«ąø²ąø£ą¹ąø„ąø°ąøąøąøąøąø“ą¹ąøąøą¹ąøą¹ąøąø“ąø§ ąøąø¶ąøąøąø³ą¹ąø«ą¹ąøąø“ąø§ąøŖąøą¹ąøŖą¹ąøąø„ą¹ąøąøąø„ąø±ą¹ąø ą¹ąø„ąø°ą¹ąø£ąøµąø¢ąøą¹ąøąøµąø¢ąø
ąøŖąø²ąø”ąø²ąø£ąøąøą¹ąø§ąø¢ąø„ąøą¹ąø„ąø·ąøąøąø£ąø“ą¹ąø§ąø£ąøąø¢ąøąøøąøąøą¹ąø²ąøąøąø³ąøą¹ąø²ąøą¹ ąøąø³ą¹ąø«ą¹ąøąø“ąø§ąøąø¹ąøą¹ąøąøąøąø§ą¹ąø²ąø§ąø±ąø¢ ąø£ąø§ąø”ąøąø±ą¹ąøąøŖąø²ąø”ąø²ąø£ąøąøąøąø±ąøąøąøąøą¹ąøŖąøµąø¢ąøąøąøąøąø²ąøą¹ąøąø„ąø„ą¹
ą¹ąø„ąø°ąø¢ąø±ąøąø”ąøµąøąø£ąø°ąøŖąø“ąøąøąø“ąø ąø²ąøą¹ąøąøąø²ąø£ąøą¹ąø§ąø¢ąø£ąø±ąøąø©ąø²ąøŖąø“ąø§ą¹ąøą¹ąøąøµąøąøą¹ąø§ąø¢ ąøąø°ąøąø³ą¹ąø«ą¹ąøąø“ąø§ąøąø²ąø§ ąøą¹ąøąøą¹ąø¢ąø²ąø§ąøą¹ ąøąø“ąø§ąøąø”ąøąø¹ą¹ąøąøąøŖąø²ąø§ą¹ąøąø²ąø«ąø„ąøµą¹ąøą¹ą¹ąøąøąø±ąøąøąøµ
ą¹ąøąø·ą¹ąøąøąø„ąø„ąø±ąøąøą¹ąøąøµą¹ą¹ąø£ą¹ąø§ąø¢ąø“ą¹ąøąøąø¶ą¹ąø ą¹ąøąø°ąøąø³ąøąø²ąøąøąø¹ą¹ąøąø±ąøąøąø„ąø¹ąøą¹ąø² ą¹ąøąø·ą¹ąøą¹ąø«ą¹ąøąø“ąø§ąøąø²ąø§ą¹ąø£ą¹ąø§ąøąø¶ą¹ąøąøąø¶ąø 2 ą¹ąøą¹ąø²
ąø§ąø“ąøąøµąøąø²ąøąøąø“ąøąøąø¹ą¹ąøąø±ąø ąøąø„ąø¹ąøą¹ąø² ąø§ąø±ąøąø„ąø° 2 ą¹ąø”ą¹ąøąøą¹ąø°
ąø£ąø²ąøąø² ąø„ąø¹ąøąøą¹ąø²ąøąø±ą¹ąø§ą¹ąø ąøąø„ąøµąø 3 ąøąø²ąø
100 ą¹ąø”ą¹ąø 2 ąøąø²ąø
500 ą¹ąø”ą¹ąø 1.5 ąøąø²ąø
1000 ą¹ąø”ą¹ąø 1 ąøąø²ąø
10000 ą¹ąø”ą¹ąø ą¹ ąøąø²ąø
ąø£ąø²ąøąø² ąøąø±ąø§ą¹ąøąø 1 ąøąø²ąø
100 ą¹ąø”ą¹ąø 1 ąøąø²ąø
500 ą¹ąø”ą¹ąø 0.9 ąøąø²ąø
1000 ą¹ąø”ą¹ąø 0.9 ąøąø²ąø
10000 ą¹ąø”ą¹ąø 0.9 ąøąø²ąø
The University of Louisville Division of Cardiovascular Medicine presented the 21st Annual Leonard Leight Lecture on December 10, 2014 in Kornhauser Auditorium on the UofL Health Sciences campus.
The special guest speaker for 2014 was Victor J. Dzau, M.D., President of the Institute of Medicine.
Dr. Dzau presented "Molecular Approaches to Cardiac Regeneration" focusing on understanding cell-based therapy for cardiac regeneration.
Vanessa Campo-Ruiz, Science Officer to the Chief Executive on assignment to the Biomedical Sciences, European Science Foundation
Adam Heathfield, Director Science Policy Europe, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
For more information about our Stem Cell Research Curriculum, please visit www.nwabr.org/curriculum/stem-cell-research
Scanning electron microscope image of newly developed foam biomaterial with just the right amount of random stickiness so that stem cells can adhere and grow into mature tissue cells. Adam Engler, Department of Bioengineering, UC San Diego Jacobs School of Engineering.
The staff at Bauman Medical Group is proud to be among the first 100% complete hair transplant teams to become certified in FDA approved Autologel PRP for Hair Restoration Surgery and Wound Healing.
Vanessa Campo-Ruiz, Science Officer to the Chief Executive on assignment to the Biomedical Sciences, European Science Foundation
Adam Heathfield, Director Science Policy Europe, Pfizer
Magda Chlebus, Director Science Policy, EFPIA
Jonathan Brenton, British Ambassador to Belgium
Duane Schulthess, Commercial Director, Science|Business
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Cell Power No.1
"LĆ½ tĘ°į»ng hĆ³a tįŗæ bĆ o & sįŗ”c Äįŗ§y nÄng lĘ°į»£ng cho tįŗæ bĆ o"
VĘ”Ģi nhĘ°Ģng Ę°u ÄiĆŖĢm vĘ°Ę”Ģ£t trĆ“Ģ£i OHUI Cell Power No.1 Äem ÄĆŖĢn cho ngĘ°Ę”Ģi sĘ°Ģ duĢ£ng caĢm giaĢc maĢt meĢ, mĘ”Ģi laĢ£ tuyĆŖĢ£t vĘ”Ģi nhįŗ„t.
ThiĢch hĘ”Ģ£p vĘ”Ģi tįŗ„t caĢ laĢn da, bĆ¢Ģt kyĢ ai cuĢng coĢ thĆŖĢ sĘ°Ģ duĢ£ng ÄĘ°į»£c.
LaĢm da saĢng raĢ£ng rĘ”Ģ, caĢi thiĆŖĢ£n nĆŖĢp nhÄn vaĢ ngÄn laĢo hoĢa.
ThĆ“ng minh vaĢ coĢ tiĢnh Ę°Ģng duĢ£ng cao, giuĢp khaĢch haĢng luĆ“n ÄĘ°Ę”Ģ£c sĘ°Ģ duĢ£ng tinh chĆ¢Ģt tĘ°Ę”i mĘ”Ģi nhĆ¢Ģt.
OHUI Cell Power No.1 cho laĢn da bĘ°Ģng tiĢnh vaĢ treĢ trung.
ThĆ nh phįŗ§n:
SCP ( Stemcell power) No 1: tĆ”i sinh tįŗæ bĆ o mįŗ§m. cung cįŗ„p nÄng lĘ°į»£ng, dung dį»ch nuĆ“i dĘ°į»”ng tįŗæ bĆ o mįŗ§m trĆŖn thĆ¢n bƬ & biį»u bƬ.
SCN No 1ā¢: cung cįŗ„p dĘ°į»”ng chįŗ„t nuĆ“i dĘ°į»”ng tįŗæ bĆ o mįŗ§m.
SCV No 1ā¢: tÄng cĘ°į»ng sį»©c sį»ng cho tįŗæ bĆ o mįŗ§m. Loįŗ”i bį» protein lĆ£o hĆ³a, tÄng cĘ°į»ng sį»©c sį»ng cho tįŗæ bĆ o mįŗ§m.
Dung tĆch: 10ml
GiĆ”: 200.000 Ä
Call: Mss Thuy - 0943 168 179
Amelia Andersdotter, Member, European Parliament
Suchitra Sumitran-Holgersson, Professor of Transplantation Biology, University of Gothenburg
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
This is the first screenshot I took in the morning of 9/11 CNN had gone to a slightly simplier home page, but there was still other top stories being listed, including the stem cell issue
I promised Rika we'd visit the Mother&Baby expo, but I was too tired to go on the 17th, so we went on the next day. It was a nice small expo, I bought a stemcell blood preservation in Singapore, we might just need it someday.
Stephanie Schissler, Matthew Schissler, Brian Krolicki, Lonnie Hammargren, Somer Hollingsworth - Cord Blood America's Las Vegas, NV Corporate Office and Lab Grand Opening
Vanessa Campo-Ruiz, Science Officer to the Chief Executive on assignment to the Biomedical Sciences, European Science Foundation
Adam Heathfield, Director Science Policy Europe, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Vanessa Campo-Ruiz, Science Officer to the Chief Executive on assignment to the Biomedical Sciences, European Science Foundation
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Anne M. Petersen, EU consultant, creoDK, Capital Region Denmark EU Office
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Medical conferences bring together a powerful mixture of mature thought leaders and the next generation of experts with the sole goal of designing and completing the advancement in the arena of cancer science & Stem Cell Research that will change the way we do research in cancer science and stem cell field for the better. Medical conferences fill a critical need for pharmaceutical sponsors, providing an unparalleled level of strategic, scientific, and operational expertise in a timely manner.
An International Conference On cancer Science & Stem Cell Research
when-29-30 July, 2019
Where- Amsterdam, Netherlands
Contact : +31728080590
cancerscience@medicalconferences.nl
www.medicalconferences.nl/conference_registration/Cancer-...
Vincent Clay, Manager, EU Government Affairs & Stakeholder Engagement, EU Representation Office, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Motor neuron progenitors (green) derived from human embryonic stem cells. Such neurons could be used to treat spinal cord injuries and diseases of the motor neurons.
This photo was taken by Sharyn Rossi in the lab of Hans Keirstead at the University of California, Irvine.
Learn more about CIRM-funded stem cell research: www.cirm.ca.gov
Shamshad Ahmed of Smart Cells International explains stem cell treatment successes.www.smartcells.com
Katherine Littler, Policy Adviser, Wellcome Trust
Amelia Andersdotter, Member, European Parliament
Suchitra Sumitran-Holgersson, Professor of Transplantation Biology, University of Gothenburg
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
The Workshop on Treatment of Hematologic Malignancies and Allogeneic Hematopoietic Stem Cell Transplantation using Alternative Donors in September 2012 was a forum for the sharing of new knowledge and the building of bridges between researchers.
Phil Holliday, European Advisor, UK Research Office (UKRO)
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Jessica Cole, Assistant to Vicky Ford, MEP, European Parliament
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen